Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial

Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib) in addition to lenalidomide and dexamethasone failed ... Read More